Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1

Interventions

pembrolizumab 244Nivolumab 140Cisplatin 135Cyclophosphamide 134Paclitaxel 113Carboplatin 108Gemcitabine 98Radiotherapy 83Dexamethasone 83Docetaxel 77atezolizumab 68Ipilimumab 68Doxorubicin 62Fluorouracil 60Blood Specimen Collection 58Bevacizumab 58fludarabine 54Rituximab 54Etoposide 53Oxaliplatin 52Surveys and Questionnaires 49Lenalidomide 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Cetuximab 44Capecitabine 44lenvatinib 43Radiosurgery 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × bomedemstat × 1 year × Clear all
NCT05558696 2026-05-07

IMG-7289-CTP-203

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed
20 enrolled 19 charts
Myeloid

Polycythemia Vera

NCT05223920 2025-09-22

MK-3543-005

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed
81 enrolled 13 charts
Myeloid

Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡